Overview
VK2735 is a novel synthetic dual agonist of the GLP-1 and GIP receptors developed by Viking Therapeutics for treatment of obesity and metabolic disorders. Available in both subcutaneous and oral formulations, it is structurally distinct from tirzepatide while targeting the same dual receptor pathway. Phase 2 VENTURE trial results published in the journal Obesity (January 2026) demonstrated up to 14.7% weight loss at 13 weeks, with Phase 3 trials (VANQUISH-1 and VANQUISH-2) currently enrolling.
Mechanism of action
VK2735 is a co-agonist designed to simultaneously activate two incretin receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). GLP-1R activation drives glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite suppression via hypothalamic and brainstem pathways. GIPR co-activation amplifies the insulinotropic response and has been shown in preclinical models to enhance adipose tissue fatty acid oxidation, reduce fat mass independently of caloric restriction, and modulate central reward pathways that drive hedonic eating. The dual receptor engagement produces synergistic weight loss beyond what GLP-1R agonism alone achieves, consistent with observations from tirzepatide. The oral formulation uses a proprietary delivery technology to overcome GLP-1 peptide degradation in the GI tract.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| obesity treatment (subcutaneous formulation — clinical trial dosing) | subcutaneous | 0.5–2.4 mg | once weekly | Phase 2 VENTURE trial used escalating doses from 0.5 mg to 2.4 mg/week over 13 weeks. Dose titration schedule mirrors tirzepatide pattern. Not available outside clinical trials. |
| obesity treatment (oral formulation — clinical trial dosing) | oral | 25–100 mg | once daily | Oral Phase 2 trial used daily dosing with 4-week titration steps. Oral bioavailability requires higher nominal dose vs. subcutaneous. Investigational only. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
The Phase 2 VENTURE trial (subcutaneous formulation, 13 weeks, n=176 adults with obesity) demonstrated mean weight loss of 13.1% at 2.4 mg/week and up to 14.7% at higher doses versus 2.2% placebo. All doses above 15 mg showed statistically significant weight loss vs. placebo by week 1. The oral Phase 2 VENTURE-Oral trial showed up to 12.2% mean weight loss at 13 weeks, with results published January 2026. Phase 3 VANQUISH program initiated 2025; pivotal outcomes pending.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with VK2735 for synergistic effects.
Legal status
Investigational compound as of 2026. Not FDA-approved. Being evaluated under IND in Phase 3 clinical trials (VANQUISH-1, VANQUISH-2). Not available by prescription; research chemical suppliers may offer non-GMP versions of uncertain purity. Viking Therapeutics retains exclusive development rights. No compounding pharmacy pathway as of 2026.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings.